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permission from the journal.Background: Intensive blood pressure lowering is
increasingly gaining attention. In addition to higher
baseline blood pressure, cumulative SBP, visit-to-visit
variability, and treatment-induced serious adverse events
(SAEs) could impact treatment efficacy over time. Our aim
was to assess the impact of cumulative SBP and SAEs on
intensive hypertension treatment efficacy in the Systolic
Blood Pressure Intervention Trial (SPRINT) population
during follow-up.
Methods: Secondary analysis of the SPRINT study: a
randomized, controlled, open-label trial including 102
clinical sites in the United States. We included 9068
SPRINT participants with 128139 repeated SBP
measurements. Participants were randomly assigned to
intensive (target SBP<120mmHg) versus standard
treatment (target SBP between 135 and 139mmHg). We
used cumulative joint models for longitudinal and survival
data analysis. Primary outcome was a composite outcome
of myocardial infarction, other acute coronary syndromes,
acute decompensated heart failure, stroke, and
cardiovascular mortality.
Results: Although intensive treatment decreased the risk
for the primary SPRINT outcome at the start of follow-up,
its effect lost significance after 3.4 years of follow-up in
the total SPRINT population and after 1.3, 1.3, 1.1, 1.8,
2.1, 1.8, and 3.4 years among participants with prevalent
chronic kidney disease, prevalent cardiovascular disease,
women, black individuals, participants less than 75 years,
those with baseline SBP more than 132mmHg, and
individuals who suffered SAEs during follow-up,
respectively.
Conclusion: The initial beneficial impact of intensive
hypertension treatment might be offset by cumulative SBP
and development of SAEs during follow-up.
Keywords: adverse effects, cumulative joint model,
intensive treatment, randomized controlled trial, SBP,
treatment efficacy
Abbreviations: cJM, cumulative joint model; CKD, chronic
kidney disease; CVD, cardiovascular disease; LMM, linear
mixed effect model; SAEs, serious adverse events; SPRINT,
Systolic Blood Pressure Intervention Trial1058 www.jhypertension.comINTRODUCTIONH
igh blood pressure (BP) is a major modifiable risk
factor for cardiovascular disease (CVD) [1,2]. In addi-
tion tohigher baselineBP, visit-to-visit variability and
cumulative exposure to BP have been linked to higher risk for
CVD and kidney dysfunction [3–5]. Intraindividual BP fluc-
tuations are not random and tend to persist within individuals
[6,7]. Therefore, the conventional approach of correlating
baseline BP with outcomes of interest in clinical trials might
lead to biased estimates regarding treatment efficacy.
Treatment of hypertension and lowering BP has been
consistently associated with beneficial clinical outcomes in
observational studies and randomized clinical trials [8]. As the
epidemiological associations of BP with cardiovascular risk
do not indicate a clear lower bound threshold [9], lowering
the BP to the lowest tolerable levels is deemed to yield the
greatest clinical benefit [10,11]. However, intensive BP low-
ering has adverse effects that could impact the efficacy of this
intervention [12]. Recent evidence from the Systolic Blood
Pressure Intervention Trial (SPRINT) showed that intensive
lowering of BP significantly reduced major vascular events
[13]. Although the frequencyof serious adverse events (SAEs)
was equal in both conventional and intensive treatment armsDOI:10.1097/HJH.0000000000002001
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Cumulative SBP and adverse events in SPRINTof the SPRINT, it remains unclear whether benefits from
intensive loweringof BPoutweigh the risk for adverse events
during the course of treatment, in particular among those
who developed SAEs, over time.
Taking into account the cumulative effect of the SBP, its
intraindividual variability and the adverse effects produced
during the follow-up, we asked the question: Do the
beneficial effects of intensive SBP reduction remain in
the long term in SPRINT total population and in each
subgroups under analysis? Using the SPRINT database,
we aimed to assess the impact of cumulative exposure to
BP on the beneficial effects of intensive hypertension
treatment. We further sought to evaluate the impact of SAEs
on the efficacy of intensive treatment during follow-up.
METHODS
Original Systolic Blood Pressure Intervention Trial
The SPRINT included 9361 hypertensive participants with
SBP between 130 and 180mmHg, older than 50 years, with
increased cardiovascular risk. Exclusion criteria were diabe-
tesmellitus, stroke, advanced chronic kidney disease (CKD),
proteinuria more than 1 g/day, polycystic kidney disease,
congestive heart failure, dementia, or residence in a nursing
home. Participants were randomly assigned to intensive
(target SBP< 120mmHg) versus standard treatment (target
SBP between 135 and 139mmHg) and were evaluated
monthly during the first trimester of follow-up and every 3
months afterwards. The trial stopped at 3.26 years median
follow-up (range 0–4.5 years) based on recommendation
from the data safetymonitoring board. Primary outcomewas
a composite of myocardial infarction, other acute coronary
syndromes, acute decompensated congestive heart failure,
stroke, and cardiovascular mortality. SAEs were the events
meeting any of the following criteria: fatal or life-threatening
event resulting in significant or persistent disability, required
or prolonged hospitalization, representing significant haz-
ards or harm to research participants potentially requiring
medical or surgical intervention [13].
Hypotension, bradycardia, falls, syncope, acute kidney
injury, and electrolytes abnormalities were SAEs included in
original SPRINT. Participants were coded having experi-
enced SAEs with the first episode, whatever it was.
Our secondary analysis of Systolic Blood
Pressure Intervention Trial
For this secondary analysis, we used the original SPRINT
database available by data request #4536 to Biologic Speci-
men and Data Repository Information Coordinating Center
repository (National Heart, Lung and Blood Institute) under
the SPRINT data analysis challenge initiative, organized by
The New England Journal of Medicine. Our research proto-
col was approved by the Ethical Committee of Universidad
Industrial de Santander, Bucaramanga, Colombia. Partici-
pants with missing data on covariates or without repeated
SBP measurements and observations occurring after the
primary event were removed. After exclusion of 293 partic-
ipants (26 primary outcomes), the current analyses included
9068 participants (97% of the original SPRINT participants)
with 128139 SBP measurements and 536 primary outcomes
(95.4% of the original SPRINT outcomes) (Fig. 1).Journal of HypertensionStatistical analysis
Two researchers independently built the long format data-
base for the analyses to ensure no data management
inconsistences. First, we focused on analyzing the SBP
longitudinal evolutions. To account for the correlations
among the repeated measurements of each patient, we
used linear mixed effects models (LMM). Initial descriptive
analysis showed that patients experienced an immediate
SBP drop after initiation of treatment (Fig. 2). To account for
this feature in both the fixed and random effects parts of the
LMM, we used natural cubic splines with internal knots
placed at 0.25, 0.5, and 1.4 years, and boundary knots (in
this case the upper knot) not to the maximum (i.e. the
default) but to the 95th percentile of the time variable (0, 3.5
year) to capture the time evolutions. We used a diagonal
covariance matrix for the random effects. The treatments
effect was included in the fixed effects part both as main
effects and interacting with the nonlinear time effect. Sec-
ond, for the primary SPRINT outcome a Cox model was
used in which again treatment was included as an explan-
atory variable. Finally, to explicitly capture the association
between the serial SBPmeasurements of eachpatient and the
hazard of the primary outcome,weutilized the framework of
joint models for longitudinal and survival outcomes [14–17].
This framework combines the two aforementioned mixed
effects and Cox models. In the specific joint model we used
(cumulative joint model – cJM), we accounted for the
cumulative exposure of SBP (that is the whole history of
SBP values of each patient) to the hazard of the primary
endpoint. Regarding treatment differences, the major
advance of joint models versus the traditional Cox model
is that they allow to disentangle the total treatment effect into
two parts (Fig. 3); namely a direct effect of treatment to the
hazard of the endpoint and an indirect effect of treatment via
SBP. We also derived the total treatment effect from the cJM
that accounts for differences in SBP values over time, and
associated 95% confidence intervals (CIs) using bootstrap-
ping (refer to Supplemental Appendix for additional infor-
mation about cJM, http://links.lww.com/HJH/B41).
In addition, we examined the distribution of different
types of SAEs in the total population and in each subgroup.
We further evaluated the risk of developing SAEs related to
the intervention type (intensive versus standard treatment)
using Cox proportional hazards analyses. We then intro-
duced an interaction term in the cJM for occurrence of SAEs
during follow-up and stratified the analyses accordingly.
Similar to the original SPRINT report, we performed sub-
group analyses among CKD/non-CKD, female/male, black/
nonblack race, age less than 75/at least 75, CVD/non-CVD,
and baseline SBP categories (132, 133–144, and
145mmHg). All analyses were performed using JM pack-
age [15] of R software (R 3.4.1; R Foundation for Statistical
Computing, Vienna, Austria).
RESULTS
Table 1 presents characteristics of the 9068 included par-
ticipants. Similar to the original SPRINT report, the intensive
and standard treatment groups are balanced in all variables.
Figure 2 shows the average SBP changes during follow-
up in the intensive and standard treatment groups (thesewww.jhypertension.com 1059
FIGURE 1 Flow chart of the original SPRINT trial participants and participants in our secondary analysis of SPRINT trial.
Rueda-Ochoa et al.averages were estimated through the fixed-effects part of
the LMM). Figure 4 shows the SBP variability within each
individual for several randomly selected participants (this
variability was estimated in all participants through the
random effects part of the LMM). The plot indicates a large
variability of SBP within individuals. Most of the decline in
SBP occurred during the first 3 months of follow-up. In the
LMM, mean SBP at baseline was 139.7mmHg in both
groups. Intensive treatment significantly reduced SBP by
an average 12.73mmHg during follow-up. This corre-
sponds to the overall difference in average SBP during
follow-up between the intensive and standard treatment
groups depicted in Fig. 2. Hazard ratio for intensive treat-
ment in the overall population, using traditional Coxmodel,
was similar to the original SPRINT report (hazard ratio; 95%
CI: 0.75; 0.63, 0.89). The cJM approach hazard ratio (95%CI)
was 0.60 (0.50, 0.72) at the start of follow-up. However, the
effect significance was lost after 3.36 years (Fig. 5).1060 www.jhypertension.comIn all subgroups, hazard ratios for intensive
treatment using traditional Cox model were similar to
the original SPRINT report. Using the cJM approach,
intensive treatment decreased the risk for the primary
outcome among all subgroups at the start of follow-up.
However, the effect lost its significance after 1.3 and 3.4
years among participants with andwithout baseline CKD,
after 1.1 and 3.5 years among women and men, after 1.8
and 3.1 years among black and nonblack individuals,
after 2.1 and 3.4 years among individuals less than 75
years and at least 75 years, after 1.3 and 3.4 years among
participants with and without prevalent CVD, after 2.5,
2.0, and 1.8 years for individuals with baseline SBP of
132mmHg or less, between 133 and 144mmHg, and at
least 145mmHg, respectively (Fig. 6a–l). Appendix
Table S1, http://links.lww.com/HJH/B41 presents the
hazard ratios (95% CIs) at the start and end of follow-
up for all subgroups.Volume 37  Number 5  May 2019
FIGURE 2 Mean SBP trajectories for the intensive treatment and standard treatment groups in Systolic Blood Pressure Intervention Trial.
FIGURE 3 Comparison between traditional Cox proportional hazards and cumulative joint model approaches in the total Systolic Blood Pressure Intervention Trial. Cox
denotes Cox proportional hazard model, LMM linear mixed effects model, SAEs serious adverse events, I. Traditional Cox model analysis. II. Joint model for longitudinal
and time-to-event-data. 1. Baseline characteristics between intervention groups are balanced by randomization. 2. Changes in SBP over time between individuals by groups
(fixed part of LMM) and changes in SBP over time within individuals by groups (random part of LMM). 3. All (including unmeasured) time varying covariates (such as SAEs)
(random part of LMM).
Cumulative SBP and adverse events in SPRINT
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TABLE 1. Baseline characteristic of the study participants
Characteristica Intensive treatment, N¼4552 Standard treatment, N¼4516 P value
Criterion for increased cardiovascular risk, n (%)b
Age 75 years 1276 (28.03) 1258 (27.86) 0.853
Chronic kidney diseasec 1296 (28.47) 1262 (27.95) 0.578
Cardiovascular disease 921 (20.23) 905 (20.04) 0.818
Clinical 762 (16.74) 757 (16.76) 0.977
Subclinical 245 (5.38) 237 (5.25) 0.776
Framingham 10-year CVD risk score 15% 2800 (61.51) 2782 (61.6) 0.928
Female sex, n (%) 1625 (35.70) 1582 (35.03) 0.506
Age (years)
Overall 67.99.4 67.89.4 0.756
Among those 75 years of age 79.83.8 79.83.9 0.846
Race or ethnic group, n (%)d
Non-Hispanic black 1338 (29.39) 1371 (30.36) 0.228
Hispanic 492 (10.81) 470 (10.41)
Non-Hispanic white 2626 (57.69) 2603 (57.64)
Other 96 (2.11) 72 (1.59)
Black racee 1413 (31.04) 1438 (31.84) 0.411
Baseline blood pressure (mmHg)
SBP 139.6715.8 139.6715.4 0.993
DBP 78.211.9 78.112.0 0.519
Distribution of SBP, n (%)
132mmHg 1543 (33.90) 1490 (33.00) 0.345
133–144 mmHg 1451 (31.88) 1504 (33.30)
145mmHg 1558 (34.23) 1522 (33.70)
Serum creatinine (mg/dl) 1.070.34 1.070.33 0.869
Estimated GFR (ml/min per 1.73m2)
Among all participants 71.8120.6 71.8320.5 0.973
Among those with estimated GFR60 81.415.5 81.115.5 0.522
Among those with estimated GFR<60 47.99.4 47.99.5 0.907
Ratio of urinary albumin (mg) to creatinine (g) 43.0174.5 41.2154.4 0.612
Fasting total cholesterol (mg/dl) 190.141.5 190.241.1 0.971
Fasting HDL cholesterol (mg/dl) 52.9214.4 52.7614.5 0.593
Fasting total triglycerides (mg/dl) 125.186.4 127.294.2 0.262
Fasting plasma glucose (mg/dl) 98.913.8 98.813.3 0.797
Statin use, n (%) 1947 (42.77) 2019 (44.71) 0.063
Aspirin use, n (%) 2348 (51.66) 2278 (50.52) 0.278
Smoking status, n (%)
Never smoked 1994 (43.80) 1990 (44.07) 0.670
Former smoker 1934 (42.49) 1936 (42.87)
Current smoker 622 (13.66) 586 (12.98)
Missing data 2 (0.04) 4 (0.09)
Framingham 10-year CVD risk score (%) 20.0610.9 20.110.8 0.789
BMIf 29.925.8 29.815.7 0.373
Antihypertensive agents 1.851.04 1.831.04 0.379
Not using antihypertensive agents, n (%) 419 (9.20) 437 (9.68) 0.442
aPlus–minus values are means SD. There were no significant differences (P<0.05) between the two groups. To convert the values for creatinine to micromoles per liter, multiply by
88.4. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for triglycerides to millimoles per liter, multiply by 0.01129. To convert the
values for glucose to millimoles per liter, multiply by 0.05551. CVD, cardiovascular disease; GFR, glomerular filtration rate; n or N, numbers.
bIncreased cardiovascular risk was one of the inclusion criteria.
cChronic kidney disease was defined as an estimated glomerular filtration rate of less than 60ml/min/1.73m2 of BSA.
dRace and ethnic group were self-reported.
eBlack race includes Hispanic black and black as part of a multiracial identification.
fThe BMI is the weight in kilograms divided by the square of the height in meters.
Rueda-Ochoa et al.SAEs occurred in 96.3% (n¼ 516) of participants who
suffered the primary outcome. Appendix Table S2, http://
links.lww.com/HJH/B41, shows distribution of SAEs by
subgroup. Using Cox proportional hazards analyses (haz-
ard ratio; 95% CI), hypotension (1.71; 1.26, 2.33), electrolyte
abnormalities (1.38; 1.07, 1.79), and acute renal failure
(1.68; 1.33, 2.12) were significantly associated with inten-
sive treatment (Table 2). In the cJM, the interaction term for
having experienced SAEs during follow-up in the overall
population was significant (P for interaction SAEs
treatment <0.0001). Therefore, we stratified the cJM anal-
yses based on occurrence of SAEs during follow-up. Cox1062 www.jhypertension.comanalyses hazard ratios (95% CI) for intensive treatment in
groups with and without SAEs were 0.74 (0.62, 0.88) and
0.25 (0.084, 0.75), respectively. Using the cJM approach, the
hazard ratios (95% CI) at the start of follow-up were 0.60
(0.50, 0.72) and 0.19 (0.06, 0.63) for the groups with and
without SAEs, respectively (Table S1, http://links.lww.com/
HJH/B41). The effect lost significance after 3.4 years for
participants with SAEs but remained significant until 4.2
years of follow-up for the non-SAEs group. The wider 95%
CI for the non-SAEs group reflects the small number of
primary outcomes in this group (n¼ 20; 4% of all primary
outcomes) (Fig. 6m and n). Finally, we evaluated theVolume 37  Number 5  May 2019
FIGURE 4 Intraindividual SBP variability during follow-up for several randomly selected Systolic Blood Pressure Intervention Trial participants.
FIGURE 5 Dynamic changes in hazard ratio for primary Systolic Blood Pressure Intervention Trial outcome over time in total population. Hazard ratio and 95% confidence
interval for intensive SBP treatment based on traditional Cox proportional hazard approach (red lines) and cumulative joint model approach (blue lines). Orange vertical line
denotes the time point at which the statistical significance of the effect estimate is lost.
Cumulative SBP and adverse events in SPRINT
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FIGURE 6 Proportional hazards and cumulative joint model approaches among Systolic Blood Pressure Intervention Trial subgroups. Hazard ratio and 95% confidence
interval for intensive SBP treatment based on traditional Cox proportional hazard approach (red lines) and cumulative joint model approach (blue lines) for different
subgroups: individuals with and without chronic kidney disease at baseline (a and b); women and men (c and d); black and nonblack ethnicities (e and f); individuals less
than 75 and at least 75 years of age (g and h); individuals with and without prevalent cardiovascular disease at baseline (i and j); baseline SBP categories of 133–144 and
132mmHg or less (k and l); subgroups with serious adverse events (m) and without serious adverse events (n) during follow-up. Orange vertical line denotes the time-point
at which the statistical significance of the effect estimate is lost in each subgroup.
Rueda-Ochoa et al.
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FIGURE 6 (Continued).
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FIGURE 6 (Continued).
Rueda-Ochoa et al.differential effect of SAEs in the SPRINT primary outcome
among interventions groups using Cox proportional analy-
sis. We found significantly three times larger effects of SAEs
on the hazard ratio for primary outcome, in the intensive
treatment group (hazard ratio: 96.95; P< 0.000) compared
with standard treatment (hazard ratio: 33.42; P< 0.000) in
the overall SPRINT population.DISCUSSION
Our secondary analysis of SPRINT confirmed that intensive
hypertension treatment lowered the risk for the primary
outcome at start of follow-up. However, the initial benefi-
cial effect was lost during follow-up in the overall popula-
tion and particularly among participants with prevalent
CKD or CVD, women, black individuals, younger partic-
ipants, and those with SBP above 132mmHg at baseline.
The beneficial effect of intensive treatment was also lost
earlier among patients who suffered SAEs during follow-up.
Conventionally, trials correlate the baseline BP values
with outcomes of interest. The original SPRINT analysis
showed a 25% reduction in the primary outcome forTABLE 2. Association of intensive treatment with serious adverse eve
Characteristic Intensive treatment, N¼4552
All serious adverse eventsa n (%) 1748 (38.40)
Specific conditions of interest
Hypotension 110 (2.42)
Syncope 104 (2.28)
Bradycardia 86 (1.89)
Electrolyte abnormality 142 (3.12)
Injurious fallb 104 (2.29)
Acute kidney injury or
acute renal failurec
192 (4.22)
Serious adverse events include conditions of interest classified as possibly or definitely related to
interval; HR, hazard ratio; N, numbers; SPRINT, Systolic Blood Pressure Intervention Trial.
aDefined as an event that was fatal or life threatening, resulting in significant or persistent disab
the investigator judged to be a significant hazard or harm to the participant that may have requ
bAn injurious fall was defined as a fall that resulted in evaluation in an emergency department
cAcute kidney injury and acute renal failure were coded if the diagnosis was listed in the hospit
continued hospitalization. A few cases of AKI were noted in an emergency department if the p
1066 www.jhypertension.comintensive treatment, using the traditional Cox approach
assuming that the benefits remain constant over time.
However, besides higher BP at baseline, cumulative expo-
sure to BP and its variability are important risk factors for
CVD and kidney dysfunction [4–6]. Our analyses simulta-
neously took into account the dependency and association
between repeated SBP measurements and time-to-event
and allowed for evaluation of both direct and indirect
(i.e. through SBP) effects of the intensive treatment [14–
17]. When cumulative effect of SBP and its variability, both
within individuals and between treatment groups, was
taken into account, the initial beneficial effect of intensive
treatment was lost during follow-up. Importantly, recent
secondary analyses of ONTARGET and TRASCEND trials
showed a higher predictive value for a composite mean SBP
over time compared with baseline or event-preceding or
time-updated SBP [18], which substantiates our approach.
Based on experimental studies, high BP variability induces
a chronic inflammatory state through activation of the
myocardial angiotensin-converting enzyme, increasing
the expression of monocyte-protein-1 and transforming
growth factor-B, resulting in ventricular hypertrophy,nts during follow-up
Standard treatment, N¼4516 HR (CI 95%) P value
1676 (37.11) 1.04 (0.98–1.12) 0.210
64 (1.42) 1.71 (1.26–2.33) 0.001
80 (1.77) 1.29 (0.96–1.73) 0.087
70 (1.55) 1.22 (0.89–1.67) 0.222
102 (2.26) 1.38 (1.07–1.79) 0.012
105 (2.33) 0.98 (0.75–1.29) 0.887
114 (2.52) 1.68 (1.33–2.12) 0.000
the intervention by the SPRINT investigators. AKI, acute kidney injury; CI, confidence
ility, requiring or prolonging a hospitalization, or was an important medical event that
ired medical or surgical intervention to prevent one of the other events listed above.
or resulted in hospitalization.
al discharge summary and was felt to be one of the top three reasons for admission or
articipant presented for one of the other conditions of interest.
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Cumulative SBP and adverse events in SPRINTremodeling and dysfunction, perivascular fibrosis, endo-
thelial injury, and kidney dysfunction [19–23].
Three recent studies investigating the association of visit-
to-visit BP variability with primary SPRINT outcome and
adverse events have led to conflicting results. Chang et al.
[24] showed no association between BP variability with
primary SPRINT outcome but a significant association with
all-cause mortality. This study, however, included only the
SBP measurements between 3 and 18 months of follow-up
and discarded about 42% (n¼ 238) of the primary SPRINT
outcomes. Moreover, they adjusted for multiple covariates
disregarding the previous treatment randomization. Goyal
et al. [25] showed SBP variability to be independently
associated with higher risk of hyponatremia among SPRINT
participants. In another post-hoc analysis among a subset of
SPRINT participants with baseline CKD, DBP variability was
associated with the primary outcome and with major SAEs
[26].
The beneficial effect of intensive treatment was lost
earlier among specific subgroups in our analyses; including
CKD participants, women, and individuals of black ethnic-
ity. Previous studies have observed larger SBP variability
among these groups, linking it to a higher vascular risk
among these individuals [23,27]. Their larger SBP variability
might explain earlier loss of beneficial effect of intensive
treatment among these individuals. Compared with older
participants, individuals younger than 75 years lost the
beneficial effect of intensive treatment earlier. Although
SBP variability increases with age, younger individuals have
shown a greater susceptibility to target organ damage
resulting from SBP variability [27]. Moreover, older patients
might respond better to medications such as diuretics due
to their beneficial impact on outcomes such as congestive
heart failure which is one component of the primary
SPRINT outcome [28]. These factors might explain earlier
loss of beneficial impact of intensive treatment among
younger individuals in our study. We also observed that
individuals with SBP more than 132mmHg at baseline and
during follow-up lost the beneficial impact of intensive
treatment earlier compared with those with SBP of 132
or less. This could be attributed to a higher SBP variability
among individuals with SBP more than 132mmHg due to
larger fluctuations in the number or dose of prescribed
antihypertensive medications in this group. It is important
to mention that the 95% CI for participants with prevalent
CKD or CVD, women, black individuals was substantially
wider than the comparison groups. However, the slope of
the graphs for participants with prevalent CKD or CVD,
women, black individuals were clearly larger compared
with non-CKD, non-CVD, male, nonblack race subgroups,
respectively (P interaction <0.0001) (Fig. 6, Supplemental
Fig. 6, http://links.lww.com/HJH/B41).
Intensive BP lowering could lead to adverse events
altering the efficacy of this intervention during follow-up.
Our study showed less benefit for intensive treatment
among individuals who experienced SAEs during follow-
up (Fig. 6m and n). Although the proportion of participants
who suffered SAEs was similar between the intensive and
standard treatment groups, type of adverse event was
different. More severe adverse events including hypoten-
sion, electrolyte abnormalities, and acute kidney injuryJournal of Hypertensionoccurred more often in the intensive treatment group. In
addition to cumulative SBP and its variability, development
of SAEs could partly explain loss of initial beneficial effect
for intensive treatment over time. A secondary analysis of
SPRINT among participants with normal renal function at
baseline showed a 1.2 ratio for developing CKD per pre-
venting one cardiovascular event [29]. The risk for mortality
and CVD among patients with renal dysfunction is between
1.2–1.8 and 1.9–2.9, respectively [30]. Projecting the
SPRINT eligibility criteria to the 1999–2006 National Health
and Nutrition Examination Survey showed that intensive
treatment prevents 107 500 deaths per-year but increases
the number of patients with SAEs to 222 600 per-year [12].
Notably, SAEs occurred in the majority of SPRINT partic-
ipants who suffered the primary outcome (96.3%). In the
intensive treatment group, SAEs were associated with
SPRINT primary outcome three times more than the SAEs
in the standard group. If SAEs increase the risk of primary
outcome, the harms of intensive hypertension treatment
might offset its potential benefits.
New guidelines for management of BP, redefine the
therapeutic target as BP less than 130/80mmHg [31,32].
For primary prevention, the guidelines recommend phar-
macology treatment among individuals with BP more than
130/80mmHg and cardiovascular risk more than 10% or
those with cardiovascular risk less than 10% but BP more
than 140/90mmHg. In secondary prevention settings, phar-
macology treatment is recommended for BPmore than 130/
80. However, our results in the subgroup of SPRINT par-
ticipants with CVD history showed earlier loss of beneficial
impact of intensive SBP treatment over time than for non-
CVD participants.
Despite the observed increasing tendency in the hazard
ratios over time, as the SPRINT terminated after median 3.26
years of follow-up (range 0–4.5 years), our findings are
only applicable to this time-window. 96.3% of patients who
developed a primary outcome suffered SAEs during follow-
up. This led to small number of events and limited power
for the analyses among participants without SAEs.
Concerns have been raised that the BP measurements in
SPRINT might not be directly comparable with those of
other trials and not readily applicable to clinical settings.
The measurement of BP in the SPRINT was unattended at
the majority of study sites [33]. Assessment of 24-h ambula-
tory BP monitoring in a subset of SPRINT participants,
demonstrated that daytime ambulatory SBP was higher
than clinic SBP, the agreement between daytime ambula-
tory SBP and clinic SBP was poor, and the difference in
ambulatory SBP between the two SPRINT treatment groups
was lower than the difference measured by clinic SBP [34].
Although a subsequent analyses of the SPRINT reported
that the SPRINT results were insensitive to whether or not
BP measurements were made in an attended manner [35], it
has been suggested that treatment arms in SPRINT could
translate into clinic SBP of 132 versus 144mmHg [36,37].
Major strength of our study is the use of a robust
statistical model which allows us to maintain the initial
SPRINT randomization in our analyses. In addition, our
approach allows for evaluation of the cumulative impact of
SBP and its variability (both intraindividual and between
groups) as well as SAEs on the primary SPRINT outcome,www.jhypertension.com 1067
Rueda-Ochoa et al.taking into account that hazard ratios may change over time
[38]. An additional benefit of using joint model analysis is
that postrandomization BP measurements are treated as an
outcome (and not as a covariate), the joint likelihood of the
BP measurements and the time to the primary endpoint are
also completely specified, thus providing valid estimates of
the treatment effect. During development of the statistical
model and for construction of different SBP trajectories over
time, we specifically took into account the initial decrease
in SBP at the beginning of follow-up. Asmodel specification
and goodness of fit are fundamental for the validity of our
results, supplemental statistical material details all the steps
we followed for development of our statistical models.
Finally, we are aware that our results may be considered
controversial, however, they are in line with what was
originally published by the SPRINT group (Fig. 4 original
publication in The New England Journal of Medicine) [13],
which showed that intensive treatment did not significantly
reduce cardiovascular risk in patients with CKD, younger
participants, women, black individuals, CVD, and those
with baseline SBP more than 132mmHg. These groups are
the same ones in which we have found that the protective
benefit of intensive treatment is lost early during follow-up.
Thus, loss of beneficial effect occurred earlier in those who
did not significantly benefit from intensive treatment in the
original SPRINT. These findings further increase confidence
in the validity of our results.
In conclusion, intensive SBP treatment lowered the risk
for the primary SPRINT outcome at the start of follow-up.
However, the initial beneficial effect was lost during follow-
up in the overall population and particularly among par-
ticipants with prevalent CKD or CVD, women, black indi-
viduals, younger participants, those with baseline SBPmore
than 132mmHg, and patients who suffered SAEs.
Our results call for caution regarding universal recom-
mendations for intensive BP treatment, particularly among
specific subgroups. In addition to potential adverse effects
from intensive treatment, the impact of cumulative SBP as
well as intraindividual SBP variability should not be dis-
missed. As the tenet of medicine ‘Primum non nocere’ must
prevail, longer term clinical trials, with focus on sustained
beneficial effects of intensive interventions over time and
on patient safety are needed. cJM analysis is a novel and not
frequently considered approach for assessment of clinical
trial data. This method adds a time-varying perspective
which approaches the conditions encountered in daily
clinical practice.
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